Literature DB >> 25126259

Evaluation and management of diabetes mellitus.

Quang Nguyen1, Loida Nguyen2, James Felicetta3.   

Abstract

Diabetes mellitus is a major public health problem with tremendous medical and economic burdens. It is the seventh leading cause of death and the number one cause of end-stage renal disease, adult blindness, impotence, and nontraumatic lower-limb amputation in the United States. People with diabetes are 2 to 4 times more likely to suffer from stroke or from cardiovascular disease, and are twice as likely to die compared with age-matched individuals without diabetes. Diabetes cost the United States around $174 billion in 2007, $58 billion of which was related to disability, work loss, and early mortality. Although there is currently no known cure for diabetes, much progress has been made over the past 2 decades to improve the diagnosis and management of diabetes. Evidence has shown that applying aggressive interventions early can prevent or delay progression to microvascular complications that increase the mortality rate in diabetes. The authors review the guidelines for optimal evaluation of diabetes mellitus and discuss the current and emerging therapeutic options available in the United States.

Entities:  

Year:  2008        PMID: 25126259      PMCID: PMC4106505     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  34 in total

1.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Authors:  Fred Whitehouse; Davida F Kruger; Mark Fineman; Larry Shen; James A Ruggles; David G Maggs; Christian Weyer; Orville G Kolterman
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

Review 2.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

3.  Standards of medical care in diabetes--2008.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

4.  Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

Authors:  Mary F Carroll; Ahmad Izard; Katrina Riboni; Mark R Burge; David S Schade
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

5.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

6.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Short-term variability in measures of glycemia and implications for the classification of diabetes.

Authors:  Elizabeth Selvin; Ciprian M Crainiceanu; Frederick L Brancati; Josef Coresh
Journal:  Arch Intern Med       Date:  2007-07-23

9.  Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.

Authors:  J-L Chiasson; R G Josse; R Gomis; M Hanefeld; A Karasik; M Laakso
Journal:  Diabetologia       Date:  2004-05-26       Impact factor: 10.122

10.  Rosiglitazone RECORD study: glucose control outcomes at 18 months.

Authors:  P D Home; N P Jones; S J Pocock; H Beck-Nielsen; R Gomis; M Hanefeld; M Komajda; P Curtis
Journal:  Diabet Med       Date:  2007-06       Impact factor: 4.359

View more
  2 in total

Review 1.  Review of strategies to enhance outcomes for patients with type 2 diabetes: payers' perspective.

Authors:  Rhonda Greenapple
Journal:  Am Health Drug Benefits       Date:  2011-09

2.  Knowledge of physicians regarding the management of Type two Diabetes in a primary care setting: the impact of online continuous medical education.

Authors:  Zahra Emami; Azam Kouhkan; Alireza Khajavi; Mohammad E Khamseh
Journal:  BMC Med Educ       Date:  2020-10-20       Impact factor: 2.463

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.